Altamira Therapeutics Ltd. (CYTO) Income Statement Analysis

See more : Capitol Federal Financial, Inc. (CFFN) Income Statement Analysis – Financial Results

Complete financial analysis of Altamira Therapeutics Ltd. (CYTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altamira Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Altamira Therapeutics Ltd. (CYTO)

Industry: Biotechnology

Sector: Healthcare

Website: https://altamiratherapeutics.com

About Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	0.00	305.62K	63.88K	174.48K	-56.00K	1.27M	322.00K	-414.00K	-67.00K	3.01M	0.00	0.00
Cost of Revenue	0.00	1.44M	2.24M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-1.14M	-2.18M	174.48K	-56.00K	1.27M	322.00K	-414.00K	-67.00K	3.01M	0.00	0.00
Gross Profit Ratio	0.00%	-372.44%	-3,407.33%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%
Research & Development	3.04M	19.68M	8.94M	2.86M	3.33M	6.69M	19.21M	24.78M	26.54M	17.70M	13.25M	3.99M
General & Administrative	3.09M	3.52M	4.90M	2.59M	3.93M	4.26M	5.15M	5.41M	4.34M	4.49M	1.31M	589.53K
Selling & Marketing	15.35K	2.38M	1.50M	95.66K	113.96K	43.82K	199.48K	45.65K	72.56K	237.72K	479.03K	86.23K
SG&A	3.12M	5.90M	6.39M	2.59M	3.93M	4.26M	5.15M	5.41M	4.34M	4.49M	1.31M	589.53K
Other Expenses	0.00	-586.73K	-409.93K	0.00	0.00	215.72K	87.59K	34.06K	62.20K	73.43K	49.42K	34.28K
Operating Expenses	6.54M	24.99M	14.92M	5.46M	7.26M	10.95M	24.36M	30.22M	30.88M	22.19M	14.62M	4.61M
Cost & Expenses	6.54M	26.44M	17.16M	5.46M	7.26M	10.95M	24.36M	30.22M	30.88M	22.19M	14.62M	4.61M
Interest Income	730.20K	969.00	3.22K	258.00	17.88K	0.00	53.57K	67.57K	37.00K	52.13K	74.04K	5.83K
Interest Expense	0.00	911.87K	189.70K	135.15K	28.63K	1.07M	1.64M	828.55K	8.00K	49.64K	50.18K	0.00
Depreciation & Amortization	5.92M	118.89K	76.36K	20.04K	30.82K	72.71K	122.78K	97.60K	92.78K	73.98K	37.52K	9.24K
EBITDA	-1.35M	-17.64M	-6.72M	-5.26M	-7.24M	-10.95M	-24.31M	-30.06M	-30.84M	-22.19M	-14.51M	-4.60M
EBITDA Ratio	0.00%	-8,511.54%	-26,643.21%	-3,027.89%	12,930.83%	-865.25%	-7,548.97%	7,260.41%	46,031.34%	-737.55%	0.00%	0.00%
Operating Income	-5.92M	-26.13M	-17.10M	-5.28M	-7.26M	-10.95M	-24.36M	-30.22M	-30.88M	-22.19M	-14.62M	-4.61M
Operating Income Ratio	0.00%	-8,550.76%	-26,767.78%	-3,028.04%	12,962.76%	-865.25%	-7,565.61%	7,300.31%	46,086.57%	-737.59%	0.00%	0.00%
Total Other Income/Expenses	-1.35M	-645.64K	-1.46M	-2.94M	433.41K	-380.10K	-66.00K	-570.03K	1.17M	4.01M	-82.89K	8.09K
Income Before Tax	-7.27M	-26.54M	-17.37M	-8.22M	-6.83M	-11.33M	-24.43M	-30.79M	-29.71M	-18.19M	-14.70M	-4.60M
Income Before Tax Ratio	0.00%	-8,683.69%	-27,188.48%	-4,712.11%	12,188.82%	-895.28%	-7,586.10%	7,438.00%	44,335.82%	-604.35%	0.00%	0.00%
Income Tax Expense	0.00	-10.33K	21.62K	-21.28K	-193.84K	162.18K	-17.77K	-131.06K	-84.78K	-892.18K	305.75K	0.00
Net Income	-7.27M	-26.53M	-17.39M	-8.20M	-6.63M	-11.50M	-24.41M	-30.66M	-29.71M	-18.19M	-15.00M	-4.60M
Net Income Ratio	0.00%	-8,680.31%	-27,222.33%	-4,699.91%	11,842.68%	-908.09%	-7,580.58%	7,406.34%	44,335.82%	-604.35%	0.00%	0.00%
EPS	-14.81	-582.58	-525.13	-545.41	-455.96	-2.89K	-22.32K	-35.73K	-36.79K	-26.27K	-33.25K	-10.20K
EPS Diluted	-14.80	-582.58	-525.13	-545.41	-455.96	-2.89K	-22.32K	-35.73K	-36.79K	-26.27K	-33.25K	-10.20K
Weighted Avg Shares Out	491.00K	45.54K	33.12K	15.04K	14.55K	3.98K	1.09K	858.20	807.40	692.30	451.30	451.30
Weighted Avg Shares Out (Dil)	491.26K	45.54K	33.12K	15.04K	14.55K	3.98K	1.09K	858.20	807.40	692.30	451.30	451.30

Altamira Therapeutics (CYTO) Stock: Why The Price Surged Today

November 12, 2021pulse2.com

The stock price of Altamira Therapeutics Ltd (NASDAQ: CYTO) increased by over 80% during intraday trading. This is why it happened.

CYTO Stock: Why It Increased Today

October 14, 2021pulse2.com

The stock price of Altamira Therapeutics Ltd. (NASDAQ: CYTO) by over 10% during intraday trading today.

Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application

October 14, 2021accesswire.com

HAMILTON, BERMUDA / ACCESSWIRE / October 14, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that...

Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference

October 6, 2021accesswire.com

HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that...

Altamira Therapeutics Provides Update on Bentrio Program

September 27, 2021accesswire.com

Building Bentrio™ brand and expanding in European markets 510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA") Distributors signed up for two key South East Asian countries, highlighting international expansion potential HAMILTON, BERMUDA /...

Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program

September 21, 2021accesswire.com

HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that it will provide a...

Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021accesswire.com

HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its Chairman and CEO,...

Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results

September 8, 2021accesswire.com

Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 Enrollment in Phase 2 trial of AM-125 for acute vertigo reached its midpoint in...